[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Shanghai Tong Ren Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":172},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,47,73,97,120,149],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100642820","posterosuperior-bundle-pacing-for-prevention-of-atrial-fibrillation-in-patients-with-sinus-node-dysfunction-100642820",false,"NCT07645066","Posterosuperior Bundle Pacing for Prevention of Atrial Fibrillation in Patients With Sinus Node Dysfunction","A Prospective, Multicenter, Randomized Controlled Trial Evaluating the Effect of Posterosuperior Bundle Pacing on Atrial Fibrillation Prevention in Patients With Sinus Node Dysfunction","PSB-AF","Inclusion Criteria:\n\n* Age ≥18 years\n* Indication for permanent pacemaker implantation, including:\n* Sinus node dysfunction, defined as at least one of the following:\n* Symptomatic sinus bradycardia\n* Tachy-brady syndrome\n* Chronotropic incompetence\n* Sinus pause \u002F arrest\n* Atrioventricular block (if present); if ventricular pacing is required, left bundle branch area pacing is planned\n* Expected survival \\>1 year\n* Panned implantation of a device capable of detecting atrial high-rate episodes\n* Willing and able to provide informed consent\n\nExclusion Criteria:\n\n* Persistent atrial fibrillation (AF) (\\>7 days), long-standing persistent AF, permanent AF, or prior atrioventricular node ablation\n* Prior cardiac implantable electronic device (CIED) requiring replacement, upgrade, or revision\n* Indication for cardioverter-defibrillator (ICD) or cardiac resynchronization therapy (CRT-D)\n* Prior cardiac surgery, severe hepatic or renal dysfunction, or other life-threatening systemic diseases\n* Acute myocardial infarction within 3 months before enrollment\n* Persistent left superior vena cava or dextrocardia\n* Pregnant or breastfeeding women, or women of childbearing potential not using effective contraception\n* Participation in another clinical trial that may interfere\n* Any condition that, in the opinion of the investigator, makes participation unsuitable","ALL","18 Years",{"count":20,"type":21},300,"ESTIMATED","INTERVENTIONAL",[24],"NA","This study aims to evaluate whether posterosuperior bundle (PSB) pacing reduces the incidence of atrial fibrillation (AF) in patients with sinus node dysfunction (SND) undergoing pacemaker implantation. Approximately 300 patients will be enrolled and randomized to receive atrial pacing at either the PSB region or the right atrial appendage (RAA). The primary endpoint is the occurrence of AF episodes lasting ≥6 minutes, as detected by device or surface electrocardiogram. Patients will be followed for up to 24 months.",[27,28],"Pacing Therapy","Cardiac Pacing",[30,31,32,33],"Posterosuperior bundle pacing","Right atrial appendage pacing","Physiological pacing","atrial pacing","NOT_YET_RECRUITING","2026-08-03",{"date":37,"type":38},"2026-08-04","ACTUAL",{"date":40,"type":21},"2026-08-14",{"date":42,"type":21},"2029-02-01",{"name":44,"class":45},"Shanghai Tong Ren Hospital","OTHER",10,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":22,"phases":57,"briefSummary":58,"conditions":59,"keywords":60,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":72},"100638995","immediate-electrophysiological-effects-of-different-atrial-pacing-sites-on-p-wave-characteristics-100638995","NCT07603648","Immediate Electrophysiological Effects of Different Atrial Pacing Sites on P-Wave Characteristics","Prospective Within-Subject Evaluation of Immediate Electrophysiological Effects of Multiple Atrial Pacing Sites on Atrial Activation and P-Wave Morphology","Multi-site AP","Inclusion Criteria:\n\n* Age ≥18 years\n* Sinus rhythm at baseline\n* Indication for permanent pacemaker implantation with planned atrial lead placement\n* Willing and able to provide written informed consent\n\nExclusion Criteria:\n\n* Long-standing persistent or permanent atrial fibrillation, or prior atrioventricular node ablation\n* Prior cardiac implantable electronic device (CIED) requiring revision, replacement, or upgrade\n* Indication for implantable cardioverter-defibrillator (ICD) or cardiac resynchronization therapy defibrillator (CRT-D)\n* Significant valvular heart disease, cardiomyopathy, or prior cardiac surgery\n* Angina or acute myocardial infarction within 3 months before enrollment\n* Chronic use of antiarrhythmic drugs\n* Severe hepatic or renal dysfunction, or other serious systemic diseases\n* Participation in another clinical study that may interfere with the objectives of this study",{"count":56,"type":21},35,[24],"This is a prospective, single-center, non-randomized, within-subject interventional study. The purpose is to compare the immediate effects of different atrial pacing sites on atrial electrical activation, as reflected by P-wave characteristics on surface electrocardiography (ECG).\n\nDuring pacemaker implantation, short-term pacing will be performed sequentially at multiple predefined atrial sites, including the right atrial appendage (RAA), atrial septum, Bachmann's bundle (BB) area, and posterosuperior bundle (PSB) regions. ECG parameters will be recorded at each site to evaluate differences in P-wave duration and morphology.",[27,28],[33,61,62,30],"physiological pacing","Bachmann's bundle pacing","RECRUITING","2026-05-18",{"date":66,"type":38},"2026-05-22",{"date":68,"type":38},"2026-03-31",{"date":70,"type":21},"2026-10-31",{"name":44,"class":45},2,{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":80,"enrollmentInfo":81,"targetDuration":4,"studyType":22,"phases":83,"briefSummary":85,"conditions":86,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":96},"100461726","phase-4-impact-of-early-pcsk9-inhibitor-treatment-on-heart-after-acute-myocardium-infarction-100461726","NCT05292404","Impact of Early PCSK9 Inhibitor Treatment on Heart After Acute Myocardium Infarction","Impact of Early PCSK9 Inhibitor Treatment on Heart After Acute Myocardium Infarction： a Muti-center, Open-label, Randomized Controlled Trial","Inclusion Criteria:\n\n1. The age is greater than 18 years old and less than or equal to 80 years old.\n2. Patients who are clinically diagnosed with STEMI onset within 24 hours and who are planning to undergo PPCI .\n3. Signed informed consent.\n\nExclusion Criteria:\n\n1. Patients who are allergic to PCSK9 inhibitors.\n2. Multivessel disease planned for selective intervention within half a year.\n3. Patients who have previously undergone revascularization.\n4. Pregnant women or women who plan to become pregnant in the next 2 years.\n5. Patients whose life expectancy is less than 1 year.\n6. Severe liver or kidney dysfunction (ALT\\>5 times ULA, eGFR\\\u003C15ml\u002Fmin\u002F1.73m2)\n7. Known active malignant tumor diseases.\n8. Patients considered by the investigator to be unsuitable to participate in this study.","75 Years",{"count":82,"type":21},160,[84],"PHASE4","This is a multi-center, prospective, randomized, controlled study. The patients with STEMI who were to undergo PPCI were divided into PCSK9 inhibitor group (n=80) and conventional treatment group (n=80) using the interactive web response system (IWRS), at a 1:1 ratio. In the PCSK9 inhibitor group, a dose of PCSK9 inhibitor (alirocumab) was injected subcutaneously immediately after PPCI and was administered every two weeks thereafter for 3 months; the control group received conventional treatment. Cardiac Magnetic Resonance Imaging (MRI) were used to measure myocardial salvage index at 1 week after operation as primary endpoints. Eject fraction at 6 months after operation will also be measured by MRI as secondary endpoints. Serum TnI\u002FT，CKMB levels were detected q8h for three times and and LDL-C levels were detected at 1 month, 3 months and 6 months after operation. Blood inflammation indicators were detected before and 1 week after the operation, and 6 months after the operation.",[87],"Acute Myocardial Infarction","2026-01-23",{"date":90,"type":38},"2026-01-27",{"date":92,"type":38},"2022-10-01",{"date":94,"type":21},"2026-12",{"name":44,"class":45},5,{"id":98,"slug":99,"hasResults":11,"nctId":100,"briefTitle":101,"officialTitle":102,"acronym":103,"eligibilityCriteria":104,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":105,"enrollmentInfo":106,"targetDuration":4,"studyType":22,"phases":108,"briefSummary":109,"conditions":110,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":72},"100418626","phase-4-impact-of-early-pcsk9-inhibitor-on-heart-after-acute-myocardium-infarction-100418626","NCT04731155","Impact of Early PCSK9 Inhibitor on Heart After Acute Myocardium Infarction","Impact of Early PCSK9 Inhibitor on Heart After Acute Myocardium","PERFECT-AMI","Inclusion Criteria:\n\n1. Subject must be at least 18 years of age and less than 80 years old\n2. Patients should have undergone successful percutaneous coronary intervention with drug-eluting stent for AMI and LAD should be the only culprit vessel.\n3. Subject understand the study requirements and the treatment procedures and provided informed consent before the procedure\n\nExclusion Criteria:\n\n1. Female of childbearing potential, unless a recent pregnancy test is negative, who possibly plan to become pregnant any time after enrollment into this study\n2. Known hypersensitivity or contraindication to study medications\n3. Plan to receive revascularization in next six month.\n4. Have received revascularization before.\n5. Subjects with life expectation less than one year.\n6. Subjects with active malignant tumor\n7. subjects with severe liver or renal dysfunction（ALT \\>5倍ULA，eGFR\\\u003C15ml\u002Fmin\u002F1.73mm2）\n8. Other conditions which the investigators think not applicable to the study.","80 Years",{"count":107,"type":21},20,[84],"This is a prospect, multi-center, random study to investigate whether early offering PCSK9 inhibitor to acute myocardium infarction(AMI) can alleviate ventricular remodeling after primary percutaneous intervention(PPCI). Totally,twenty acute myocardium infarction subjects will be enrolled in this study after consent information. After randomization, the control group will receive standard therapy for AMI including PPCI. The experiment group will receive first PCSK9 inhibitor before PPCI, then twice a month until 3 months later. Six month after AMI, Myocardial salvage index will be used to evaluate ventricular remodeling. TnI peaking time and LDL control rates also will be recorded and compared.",[111],"Early PCSK9 Inhibitor on Ventricular Remodling","2025-05-16",{"date":114,"type":38},"2025-05-21",{"date":116,"type":38},"2021-04-12",{"date":118,"type":21},"2025-10",{"name":44,"class":45},{"id":121,"slug":122,"hasResults":11,"nctId":123,"briefTitle":124,"officialTitle":125,"acronym":126,"eligibilityCriteria":127,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":128,"targetDuration":4,"studyType":22,"phases":130,"briefSummary":132,"conditions":133,"keywords":136,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":141,"startDateStruct":143,"completionDateStruct":145,"leadSponsor":147,"locationsCount":148},"100495882","phase-2-adaptive-treatment-for-acute-myeloid-leukemia-based-on-d14-mrd-results-100495882","NCT05736978","Adaptive Treatment for Acute Myeloid Leukemia Based on D14 MRD Results","Clinical Efficacy and Safety of Adaptive Treatment of Acute Myeloid Leukemia (AML) Based on D14 MRD results-a Multicenter, Single-arm, Prospective Clinical Study","AVS","Inclusion Criteria:\n\n* Known and written informed consent voluntarily\n* Age ≥ 18 years\n* Newly diagnosed AML patients (per WHO 2022 classification criteria for AML diagnosis), who are not suitable for intensive chemotherapy:\n\n  * 75 years or Aged 18 to 74 years with at least one of the following comorbidities: Eastern Cooperative Oncology Group (ECOG) performance status score of 2 or 3 or 4; Cardiac history of Congestive Heart Failure (CHF) requiring treatment or Ejection Fraction \\\u003C= 50% or chronic stable angina; Diffusing capacity of the Lung for Carbon Monoxide (DLCO) \\\u003C= 65% or Forced Expiratory Volume in 1 second (FEV1) \\\u003C= 65%; Creatinine clearance \\>= 30 mL\u002Fmin to \\\u003C 45 ml\u002Fmin; Moderate hepatic impairment with total bilirubin \\> 1.5 to \\\u003C= 3.0 × Upper Limit of Normal (ULN); Any other comorbidity that the physician judges to be incompatible with intensive chemotherapy .\n* Liver function meets the following criteria: aspartate aminotransferase (AST) ≤ 3.0×ULN\\*; alanine aminotransferase (ALT) ≤3.0×ULN\\*; Bilirubin≤1.5×ULN\\*; For subjects \\\u003C75 years old, the bilirubin level can be ≤3.0×ULN; Unless due to leukemic organ involvement.\n* Renal function meets the following criteria: creatinine clearance ≥ 30 mL\u002Fmin (Cockroft-Gault formula)\n* Life expectancy ≥ 4 weeks\n\nExclusion Criteria:\n\n* History of any malignancies prior to study entry with exception noted in the protocol.\n* Participant has known HIV infection, active hepatitis B virus (HBV) and\u002For hepatitis C virus (HCV) .\n* Participant has known active central nervous system (CNS) involvement with AML.\n* Must not have received prior anti-AML treatment except for hydroxyurea",{"count":129,"type":21},58,[131],"PHASE2","This is a prospective, single-arm, multi-center clinical trial to evaluate the efficacy and safety of selinexor in combination with azacitidine and venetoclax for untreated acute myeloid leukemia based on MRD results on day 14 of the first cycle.",[134,135],"AML","MRD",[137,138,139],"untreated AML","MRD results","selinexor","2023-03-13",{"date":142,"type":38},"2023-03-15",{"date":144,"type":21},"2023-03-31",{"date":146,"type":21},"2027-03-15",{"name":44,"class":45},4,{"id":150,"slug":151,"hasResults":11,"nctId":152,"briefTitle":153,"officialTitle":154,"acronym":155,"eligibilityCriteria":156,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":157,"targetDuration":4,"studyType":22,"phases":158,"briefSummary":159,"conditions":160,"keywords":162,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":165,"startDateStruct":166,"completionDateStruct":168,"leadSponsor":170,"locationsCount":171},"100495881","phase-2-a-study-of-selinexor-in-combination-with-azacitidine-and-venetoclax-sav-regimen-in-treatment-nave-participants-with-acute-myeloid-leukemia-100495881","NCT05736965","A Study of Selinexor in Combination With Azacitidine and Venetoclax (SAV Regimen) in Treatment Naïve Participants With Acute Myeloid Leukemia","Clinical Efficacy and Safety of Selinexol Combined With Azacitidine and Venetoclax (SAV Regimen) in the Treatment of Acute Myeloid Leukemia (AML)-a Multi-center, Single-arm, Prospective Clinical Study","SAV","Inclusion Criteria:\n\n* Known and written informed consent voluntarily\n* Age ≥ 18 years\n* Newly diagnosed AML patients (per WHO 2022 classification criteria for AML diagnosis), who are not suitable for intensive chemotherapy:\n\n  * ≥75 years or\n  * Aged 18 to 74 years with at least one of the following comorbidities: Eastern Cooperative Oncology Group (ECOG) performance status score of 2 or 3 or 4; Cardiac history of Congestive Heart Failure (CHF) requiring treatment or Ejection Fraction \\\u003C= 50% or chronic stable angina; Diffusing capacity of the Lung for Carbon Monoxide (DLCO) \\\u003C= 65% or Forced Expiratory Volume in 1 second (FEV1) \\\u003C= 65%; Creatinine clearance \\>= 30 mL\u002Fmin to \\\u003C 45 ml\u002Fmin; Moderate hepatic impairment with total bilirubin \\> 1.5 to \\\u003C= 3.0 × Upper Limit of Normal (ULN); Any other comorbidity that the physician judges to be incompatible with intensive chemotherapy .\n* patients who are suitable for intensive chemotherapy but refuse it\n* Liver function meets the following criteria:\n\naspartate aminotransferase (AST) ≤ 3.0×ULN\\*; alanine aminotransferase (ALT) ≤ 3.0×ULN\\*; Bilirubin≤1.5×ULN\\*; For subjects \\\u003C75 years old, the bilirubin level can be ≤3.0×ULN;\n\n* Unless due to leukemic organ involvement.\n\n  * Renal function meets the following criteria: creatinine clearance ≥ 30 mL\u002Fmin (Cockroft-Gault formula)\n  * Life expectancy ≥ 4 weeks\n\nExclusion Criteria:\n\n* History of any malignancies prior to study entry with exception noted in the protocol.\n* Participant has known HIV infection, active hepatitis B virus (HBV) and\u002For hepatitis C virus (HCV) .\n* Participant has known active central nervous system (CNS) involvement with AML.\n* Must not have received prior anti-AML treatment except for hydroxyurea",{"count":129,"type":21},[131],"This is a prospective, single-arm, multi-center clinical trial to evaluate the efficacy and safety of selinexor in combination with azacitidine and venetoclax for untreated acute myeloid leukemia.",[161],"AML, Adult",[139,137,163,164],"azacitidine","venetoclax",{"date":142,"type":38},{"date":167,"type":38},"2023-02-20",{"date":169,"type":21},"2027-04-30",{"name":44,"class":45},19,""]